Tag - ORGO

Developments

FDA accepts Organogenesis’ ReNu BLA for knee OA

Organogenesis Holdings (NASDAQ: ORGO) has announced that the FDA has accepted for review its Biologics License Application (BLA) for ReNu, a cryopreserved, amniotic suspension allograft developed for the treatment of...

July 7, 2026

Markets

SVB Leerink starts Organogenesis at OP; PT $9

SVC Leerink initiated coverage of Organogenesis (NASDAQ:ORGO) with an “outperform” rating and $9 price target. The stock closed at $4.84 on Jan. 9. Organogenesis is a regenerative medicine company with a portfolio of...

January 10, 2020

Tag - ORGO

FDA accepts Organogenesis’ ReNu BLA for knee OA

SVB Leerink starts Organogenesis at OP; PT $9

Subscribe